Polyus Finance Plc

  • ISIN: XS1533922933
  • Land: United Kingdom

Nachricht vom 22.08.2019 | 18:40

PJSC Polyus: 1H 2019 dividend recommendation

DGAP-News: Polyus Finance Plc / Key word(s): Dividend

22.08.2019 / 18:40
The issuer is solely responsible for the content of this announcement.


Press Release 22 August 2019

PJSC Polyus

1H 2019 dividend recommendation

The Board of Directors (the "Board") of PJSC Polyus (LSE, MOEX - PLZL) ("Polyus", or the "Company") is recommending the dividends for the first six months ended 30 June 2019 in the amount of 162.98 Russian roubles per ordinary share.

The dividend amount is equivalent to approximately 2.46 U.S. dollars per ordinary share, or 1.23 U.S. dollars per depositary share (with two depositary shares representing interest in one ordinary share).[1]

The total recommended dividend payout for the first half of 2019 will amount to 21,708,394,906.40 Russian roubles and correspond to 327.6 million U.S. dollars, representing 30% of the Company's EBITDA for the first half of 2019, in line with the Company's dividend policy.

The dividend is subject to approval by the Company's Extraordinary General Shareholders' Meeting on 30 September 2019. The dividend record date will be 10 October 2019.


Polyus
Polyus is the largest gold producer in Russia and one of the top 10 gold miners globally with the lowest cost position. Based on its 2018 Ore Reserves and Mineral Resources, the Polyus group ranks the third by attributable gold reserves and gold resources among the world's largest gold mining companies.

The Polyus group's principal operations are located in Krasnoyarsk, Irkutsk and Magadan regions and the Republic of Sakha (Yakutia).


Enquiries
Investor contact
Victor Drozdov, Director Investor Relations
+7 (495) 641 33 77
drozdovvi@polyus.com

Media contact
Victoria Vasilyeva, Director Public Relations
+7 (495) 641 33 77
vasilevavs@polyus.com
 

Forward-looking statements

This announcement may contain "forward-looking statements" concerning Polyus and/or Polyus Group. Generally, the words "will", "may", "should", "could", "would", "can", "continue", "opportunity", "believes", "expects", "intends", "anticipates", "estimates" or similar expressions identify forward-looking statements. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Forward-looking statements include statements relating to future capital expenditures and business and management strategies and the expansion and growth of Polyus' and/or Polyus Group's operations. Many of these risks and uncertainties relate to factors that are beyond Polyus' and/or Polyus Group's ability to control or estimate precisely and therefore undue reliance should not be placed on such statements which speak only as of the date of this announcement. Polyus and/or any Polyus Company assumes no obligation in respect of, and does not intend to update, these forward-looking statements, except as required pursuant to applicable law.



[1] Based on the currency exchange rate of the Central Bank of Russia of 66.263 Russian roubles per 1 U.S. dollar as of 22 August 2019.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.



22.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktuelle Research-Studie

OpenLimit Holding AG

Original-Research: OpenLimit Holding AG (von First Berlin Equity Research GmbH): Buy

14. Oktober 2019